Introduction
BRCA mutation
Discussion
Characteristic of patients | No. of patients | Type of therapy | Results | References | |
---|---|---|---|---|---|
Locally advanced PC | Patients with advanced PC | 36 | Capecitabine + RT | OS = 17.6 months PFS = 12 months | Hurt et al. (2017) |
38 | Gemcitabine + RT | OS = 14.6 months PFS = 10.4 months | |||
Patients with BRCA1 or 2 mutation and advanced PDAC, after gemcitabine treatment failure | 23 | PARPi (olaparib) | OS = 9.8 months PFS = 4.6 months | Kaufman et al. (2015) | |
Patients with advanced PC after gemcitabine treatment failure | 76 | Oxaliplatin + FA + FU | OS = 5.9 months PFS = 2.9 months | Oettle et al. (2014) | |
84 | FA + FU | OS = 3.3 months PFS = 2.0 months | |||
Metastatic PC | Patients with BRCA1 or 2 mutation and stage III/IV PDAC | 22 | Platinum based adjuvant therapy | OS = 22 months | Golan et al. (2014) |
21 | Non-platinum therapy | OS = 9 months | |||
Patients with metastatic PC | 83 | Gemcitabine + paclitaxel | OS = 9.2 months PFS = 5.5 months | Xu et al. (2017) | |
Patients with metastatic PC after gemcitabine treatment failure | 18 | FOLFIRINOX | OS = 9.8 months PFS = 2.8 months | Kobayashi et al. (2017) | |
Patients with metastatic PC after gemcitabine treatment failure | 17 | Lapatinib + capecitabine | OS = 5.2 months PFS = 2.6 months | Wu et al. (2015) |